Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share.
November 30, 2022
· 4 min read